{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:34:10Z","timestamp":1740141250248,"version":"3.37.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T00:00:00Z","timestamp":1547683200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 81773499","No. 81502853"],"award-info":[{"award-number":["No. 81773499","No. 81502853"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 81703273"],"award-info":[{"award-number":["No. 81703273"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["No. BK20171054"],"award-info":[{"award-number":["No. BK20171054"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"crossref","award":["No.BK20151026"],"award-info":[{"award-number":["No.BK20151026"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Jiangsu Program for Young Medical Talents","award":["No. QNRC2016616"],"award-info":[{"award-number":["No. QNRC2016616"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12985-018-1114-4","type":"journal-article","created":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T14:04:17Z","timestamp":1547733857000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of ombitasvir\/paritaprevir\/ritonavir, dasabuvir for HCV in HIV\/HCV coinfected subjects: a comprehensive analysis"],"prefix":"10.1186","volume":"16","author":[{"given":"Jingjing","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haozhi","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueshan","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuqiang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangyu","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,17]]},"reference":[{"issue":"34","key":"1114_CR1","doi-asserted-by":"publisher","first-page":"12132","DOI":"10.3748\/wjg.v20.i34.12132","volume":"20","author":"LN Clausen","year":"2014","unstructured":"Clausen LN, Lundbo LF, Benfield T. Hepatitis C virus infection in the human immunodeficiency virus infected patient. World J Gastroenterol. 2014;20(34):12132\u201343.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"1114_CR2","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/hiv.12429","volume":"18","author":"L Milazzo","year":"2017","unstructured":"Milazzo L, Lai A, Calvi E, Ronzi P, Micheli V, Binda F, Ridolfo AL, Gervasoni C, Galli M, Antinori S, et al. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV\/HIV-coinfected patients: real-life safety and efficacy. HIV medicine. 2017;18(4):284\u201391.","journal-title":"HIV medicine"},{"issue":"Suppl 5","key":"1114_CR3","doi-asserted-by":"publisher","first-page":"S355","DOI":"10.1016\/j.dld.2013.09.001","volume":"45","author":"M Puoti","year":"2013","unstructured":"Puoti M, Rossotti R, Travi G, Panzeri C, Morreale M, Chiari E, Cocca G, Orso M, Moioli MC. Optimizing treatment in HIV\/HCV coinfection. Dig Liver Dis. 2013;45(Suppl 5):S355\u201362.","journal-title":"Dig Liver Dis"},{"issue":"3","key":"1114_CR4","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1310\/hct1303-142","volume":"13","author":"M Rodriguez-Torres","year":"2012","unstructured":"Rodriguez-Torres M, Slim J, Bhatti L, Sterling R, Sulkowski M, Hassanein T, Serrao R, Sola R, Bertasso A, Passe And S, et al. Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial. HIV Clin Trials. 2012;13(3):142\u201352.","journal-title":"HIV Clin Trials"},{"issue":"21","key":"1114_CR5","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1056\/NEJMe1403619","volume":"370","author":"TJ Liang","year":"2014","unstructured":"Liang TJ, Ghany MG. Therapy of hepatitis C--back to the future. N Engl J Med. 2014;370(21):2043\u20137.","journal-title":"N Engl J Med"},{"key":"1114_CR6","unstructured":"Rios MJ, Perez-Perez M, Tellez F, Palacios R, Perez AB, Mancebo M, Rivero A, Macias J, Berenguer J. All-oral DAA therapy against HCV in HIV\/HCV-coinfected subjects in real-world practice: Madrid-CoRe findings. HIV Clin Trials. 2018."},{"issue":"3","key":"1114_CR7","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3949\/ccjm.81a.13155","volume":"81","author":"M Dugum","year":"2014","unstructured":"Dugum M, O'Shea R. Hepatitis C virus: here comes all-oral treatment. Cleve Clin J Med. 2014;81(3):159\u201372.","journal-title":"Cleve Clin J Med"},{"issue":"7","key":"1114_CR8","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1056\/NEJMc1307589","volume":"369","author":"R Ozaras","year":"2013","unstructured":"Ozaras R, Yemisen M, Balkan II. Current and future therapies for hepatitis C virus infection. N Engl J Med. 2013;369(7):679.","journal-title":"N Engl J Med"},{"issue":"3","key":"1114_CR9","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/MOG.0000000000000062","volume":"30","author":"ML Shiffman","year":"2014","unstructured":"Shiffman ML. Hepatitis C virus therapy in the direct acting antiviral era. Curr Opin Gastroenterol. 2014;30(3):217\u201322.","journal-title":"Curr Opin Gastroenterol"},{"issue":"4","key":"1114_CR10","first-page":"290","volume":"31","author":"P Solbach","year":"2015","unstructured":"Solbach P, Wedemeyer H. The new era of interferon-free treatment of chronic hepatitis C. Viszeralmedizin. 2015;31(4):290\u20136.","journal-title":"Viszeralmedizin"},{"issue":"6","key":"1114_CR11","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1080\/17474124.2017.1309284","volume":"11","author":"R Flisiak","year":"2017","unstructured":"Flisiak R, Flisiak-Jackiewicz M. Ombitasvir and paritaprevir boosted with ritonavir and combined with dasabuvir for chronic hepatitis C. Expert Rev Gastroenterol Hepatol. 2017;11(6):559\u201367.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"17","key":"1114_CR12","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1056\/NEJMoa1401561","volume":"370","author":"S Zeuzem","year":"2014","unstructured":"Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourliere M, Sulkowski MS, Wedemeyer H, Tam E, Desmond P, et al. Retreatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1604\u201314.","journal-title":"N Engl J Med"},{"issue":"21","key":"1114_CR13","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","volume":"370","author":"F Poordad","year":"2014","unstructured":"Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, Shiffman ML, Wedemeyer H, Berg T, Yoshida EM, et al. ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370(21):1973\u201382.","journal-title":"N Engl J Med"},{"issue":"3","key":"1114_CR14","first-page":"ofx154","volume":"4","author":"A Gil-Martin","year":"2017","unstructured":"Gil-Martin A, Jarrin I, Moreno A, Dominguez L, Montes M, Aldamiz-Echevarria T, Tellez MJ, Santos I, Benitez L, Sanz J, et al. Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir +\/\u2212 Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2. Hepatol. 2017;4(3):ofx154.","journal-title":"Hepatol"},{"issue":"5","key":"1114_CR15","first-page":"359","volume":"26","author":"L Wei","year":"2018","unstructured":"Wei L, Cheng J, Luo J, Li ZP, Duan JL, Hou JD, Jia MX, Zhang Y, Huang Q, Xie GJ, et al. Efficacy and safety of paritaprevir\/ritonavir\/ombitasvir combined with dasabuvir in non-cirrhotic Asian adult patients with newly diagnosed and treated chronic HCV genotype 1b infection: a randomized, double-blind, placebo-controlled study - China data. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology. 2018;26(5):359\u201364.","journal-title":"Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology"},{"issue":"2","key":"1114_CR16","doi-asserted-by":"crossref","first-page":"139","DOI":"10.15403\/jgld.2014.1121.272.100","volume":"27","author":"S Iacob","year":"2018","unstructured":"Iacob S, Cerban R, Pietrareanu C, Ester C, Iacob R, Gheorghe C, Popescu I, Gheorghe L. 100% sustained virological response and fibrosis improvement in real-life use of direct acting antivirals in genotype-1b recurrent hepatitis C following liver transplantation. J Gastrointestin Liver Dis. 2018;27(2):139\u201344.","journal-title":"J Gastrointestin Liver Dis"},{"issue":"1","key":"1114_CR17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/15284336.2018.1436637","volume":"19","author":"JA Pineda","year":"2018","unstructured":"Pineda JA, Rivero-Juarez A, de Los SI, Collado A. Paritaprevir\/ritonavir\/ombitasvir plus dasabuvir in HIV\/HCV-coinfected patients with genotype 1 in real-life practice. HIV Clin Trials. 2018;19(1):23\u201330.","journal-title":"HIV Clin Trials"},{"issue":"4","key":"1114_CR18","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/infdis\/jiw597","volume":"215","author":"D Wyles","year":"2017","unstructured":"Wyles D, Saag M, Viani RM, Lalezari J, Adeyemi O, Bhatti L, Khatri A, King JR, Hu YB, Trinh R, et al. TURQUOISE-I part 1b: Ombitasvir\/Paritaprevir\/ritonavir and Dasabuvir with ribavirin for hepatitis C virus infection in HIV-1 Coinfected patients on Darunavir. J Infect Dis. 2017;215(4):599\u2013605.","journal-title":"J Infect Dis"},{"issue":"15\u201316","key":"1114_CR19","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00508-016-1162-y","volume":"129","author":"S Steiner","year":"2017","unstructured":"Steiner S, Bucsics T, Schwabl P, Mandorfer M, Scheiner B, Aichelburg MC, Grabmeier-Pfistershammer K, Ferenci P, Trauner M, Peck-Radosavljevic M, et al. Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna. Wien Klin Wochenschr. 2017;129(15\u201316):517\u201326.","journal-title":"Wien Klin Wochenschr"},{"issue":"3","key":"1114_CR20","doi-asserted-by":"publisher","first-page":"ofx154","DOI":"10.1093\/ofid\/ofx154","volume":"4","author":"JK Rockstroh","year":"2017","unstructured":"Rockstroh JK, Orkin C, Viani RM, Wyles D, Luetkemeyer AF, Lazzarin A, Soto-Malave R, Nelson MR, Bhagani SR, HHF K, et al. Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir +\/\u2212 Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2. Open Forum Infect Dis. 2017;4(3):ofx154.","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"1114_CR21","first-page":"680","volume":"64","author":"A Massimo","year":"2017","unstructured":"Massimo A, Teti E, Antinori A, Milazzoi L, Sollima S, Rizzardini G, Di Biagio A, Saracino A, Bruno R, Borghi V, et al. Ombitasvir\/Paritaprevir\/ritonavir and Dasabuvir combination treatment in patients with HIV\/HCV co-infection: results of an Italian compassionate use program. Clin Infect Dis. 2017;64(5):680\u20133.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"1114_CR22","first-page":"1711","volume":"64","author":"D Bhattacharya","year":"2017","unstructured":"Bhattacharya D, Belperio PS, Shahoumian TA, Loomis TP, Goetz MB, Mole LA, Backus LI. Effectiveness of all-Oral antiviral regimens in 996 human immunodeficiency virus\/hepatitis C virus genotype 1-Coinfected patients treated in routine practice. Lancet Gastroenterol Hepatol. 2017;64(12):1711\u201320.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12","key":"1114_CR23","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1001\/jama.2015.1328","volume":"313","author":"MS Sulkowski","year":"2015","unstructured":"Sulkowski MS, Eron JJ, Wyles D, Trinh R, Lalezari J, Wang C, Slim J, Bhatti L, Gathe J, Ruane PJ, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. Jama. 2015;313(12):1223\u201331.","journal-title":"Jama"},{"issue":"9","key":"1114_CR24","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1097\/QAD.0000000000001465","volume":"31","author":"ML Montes","year":"2017","unstructured":"Montes ML, Olveira A, Ahumada A, Aldamiz T, Garcia-Samaniego J, Clemente A, Berenguer J, Gonzalez-Garcia J, Martin-Carbonero L. Similar effectiveness of direct-acting antiviral against hepatitis C virus in patients with and without HIV infection. AIDS (London, England). 2017;31(9):1253\u201360.","journal-title":"AIDS (London, England)"},{"issue":"11","key":"1114_CR25","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1111\/jvh.12722","volume":"24","author":"H Wedemeyer","year":"2017","unstructured":"Wedemeyer H, Craxi A, Zuckerman E, Dieterich D, Flisiak R, Roberts SK, Pangerl A, Zhang Z, Martinez M, Bao Y, et al. Real-world effectiveness of ombitasvir\/paritaprevir\/ritonavir+\/\u2212dasabuvir+\/\u2212ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: a meta-analysis. J Viral Hepat. 2017;24(11):936\u201343.","journal-title":"J Viral Hepat"},{"issue":"4","key":"1114_CR26","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/j.1365-2893.2006.00824.x","volume":"14","author":"NJ Shire","year":"2007","unstructured":"Shire NJ, Welge JA, Sherman KE. Response rates to pegylated interferon and ribavirin in HCV\/HIV coinfection: a research synthesis. J Viral Hepat. 2007;14(4):239\u201348.","journal-title":"J Viral Hepat"},{"issue":"9986","key":"1114_CR27","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1016\/S0140-6736(15)60159-3","volume":"385","author":"C Hezode","year":"2015","unstructured":"Hezode C, Asselah T, Reddy KR, Hassanein T, Berenguer M, Fleischer-Stepniewska K, Marcellin P, Hall C, Schnell G, Pilot-Matias T, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet. 2015;385(9986):2502\u20139.","journal-title":"Lancet"},{"issue":"8","key":"1114_CR28","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1080\/14656566.2016.1176143","volume":"17","author":"M Lucejko","year":"2016","unstructured":"Lucejko M, Parfieniuk-Kowerda A, Flisiak R. Ombitasvir\/paritaprevir\/ritonavir plus dasabuvir combination in the treatment of chronic HCV infection. Expert Opin Pharmacother. 2016;17(8):1153\u201364.","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"1114_CR29","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/jvh.12800","volume":"25","author":"C Weil","year":"2018","unstructured":"Weil C, Mehta D, Koren G, Pinsky B, Samp JC, Chodick G, Shalev V. Sustained virological response to ombitasvir\/paritaprevir\/ritonavir and dasabuvir treatment for hepatitis C: real-world data from a large healthcare provider. J Viral Hepat. 2018;25(2):144\u201351.","journal-title":"J Viral Hepat"},{"issue":"4","key":"1114_CR30","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1002\/hep.26141","volume":"57","author":"K Mohd Hanafiah","year":"2013","unstructured":"Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatol. 2013;57(4):1333\u201342.","journal-title":"Hepatol"},{"issue":"11","key":"1114_CR31","doi-asserted-by":"publisher","first-page":"3108","DOI":"10.1007\/s10620-016-4291-2","volume":"61","author":"QF He","year":"2016","unstructured":"He QF, Zhang QF, Zhang DZ. Efficacy and safety of ribavirin with Sofosbuvir plus Ledipasvir in patients with genotype 1 hepatitis C: a Meta-analysis. Dig Dis Sci. 2016;61(11):3108\u201317.","journal-title":"Dig Dis Sci"},{"issue":"11","key":"1114_CR32","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s40261-017-0565-5","volume":"37","author":"H Ahmed","year":"2017","unstructured":"Ahmed H, Abushouk AI, Menshawy A, Mohamed A, Negida A, Loutfy SA, Abdel-Daim MM. Safety and efficacy of Ombitasvir\/Paritaprevir\/ritonavir and Dasabuvir with or without ribavirin for treatment of hepatitis C virus genotype 1: a systematic review and Meta-analysis. Clinical drug investigation. 2017;37(11):1009\u201323.","journal-title":"Clinical drug investigation"},{"issue":"17","key":"1114_CR33","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","volume":"370","author":"JJ Feld","year":"2014","unstructured":"Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, Weiland O, Aguilar H, Xiong J, Pilot-Matias T, et al. Treatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1594\u2013603.","journal-title":"N Engl J Med"},{"key":"1114_CR34","first-page":"2","volume":"6","author":"JA Gonzales Zamora","year":"2018","unstructured":"Gonzales Zamora JA. Adverse Effects of Direct Acting Antivirals in HIV\/HCV Coinfected Patients: A 4-Year Experience in Miami, Florida. Diseases (Basel, Switzerland). 2018;6:2.","journal-title":"Diseases (Basel, Switzerland)"},{"issue":"5","key":"1114_CR35","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/jcpt.12426","volume":"41","author":"VL Ferreira","year":"2016","unstructured":"Ferreira VL, Assis Jarek NA, Tonin FS, Borba HH, Wiens A, Pontarolo R. Safety of interferon-free therapies for chronic hepatitis C: a network meta-analysis. J Clin Pharm Ther. 2016;41(5):478\u201385.","journal-title":"J Clin Pharm Ther"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-018-1114-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12985-018-1114-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-018-1114-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,22]],"date-time":"2020-11-22T20:06:22Z","timestamp":1606075582000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-018-1114-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,17]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1114"],"URL":"https:\/\/doi.org\/10.1186\/s12985-018-1114-4","relation":{},"ISSN":["1743-422X"],"issn-type":[{"type":"electronic","value":"1743-422X"}],"subject":[],"published":{"date-parts":[[2019,1,17]]},"assertion":[{"value":"19 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"11"}}